Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Erica N Heying"'
Autor:
Frank A. Sinicrope, Kandavel Shanmugam, Steven R. Alberts, Michael Barnes, Wen-Wei Liu, Rebecca Bowermaster, June Clements, Azita Djalilvand, Faith Ough, Joerg Bredno, Andrea Muranyi, Erica N. Heying, Qian Shi, Harry H. Yoon
Table S1. Inter-tumor heterogeneity of T-cell densities in tumor microenvironment in dMMR vs pMMR stage III colon cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f1923e7a7b6d7f8a7a4c8f7968dcac9
https://doi.org/10.1158/1078-0432.22473723
https://doi.org/10.1158/1078-0432.22473723
Autor:
Frank A. Sinicrope, Kandavel Shanmugam, Steven R. Alberts, Michael Barnes, Wen-Wei Liu, Rebecca Bowermaster, June Clements, Azita Djalilvand, Faith Ough, Joerg Bredno, Andrea Muranyi, Erica N. Heying, Qian Shi, Harry H. Yoon
Table S3: Association between T-cell subtypes and covariates in MMR-deficient and -proficient stage III colon cancers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42a9dbcc8ee531d3c0831a4277c6e20a
https://doi.org/10.1158/1078-0432.22473717
https://doi.org/10.1158/1078-0432.22473717
Autor:
Frank A. Sinicrope, Kandavel Shanmugam, Steven R. Alberts, Michael Barnes, Wen-Wei Liu, Rebecca Bowermaster, June Clements, Azita Djalilvand, Faith Ough, Joerg Bredno, Andrea Muranyi, Erica N. Heying, Qian Shi, Harry H. Yoon
Figure S1 Study flow of N0147 patient tumor samples Figure S2 Heterogeneity of lymphocytic infiltrate between patients in mismatch repair deficient (dMMR) and proficient (pMMR) tumors. The distribution of T-cell densities (score 0-100) are shown as f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::269fb33d6305dda3d848d9497f687eb0
https://doi.org/10.1158/1078-0432.22473729.v1
https://doi.org/10.1158/1078-0432.22473729.v1
Autor:
Frank A. Sinicrope, Kandavel Shanmugam, Steven R. Alberts, Michael Barnes, Wen-Wei Liu, Rebecca Bowermaster, June Clements, Azita Djalilvand, Faith Ough, Joerg Bredno, Andrea Muranyi, Erica N. Heying, Qian Shi, Harry H. Yoon
Table S2: Association between immune T-cell subtypes in MMR-deficient and -proficient stage III colon cancers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad55102e3a4781f4870b58fde44b97f8
https://doi.org/10.1158/1078-0432.22473720.v1
https://doi.org/10.1158/1078-0432.22473720.v1
Autor:
Frank A. Sinicrope, Kandavel Shanmugam, Steven R. Alberts, Michael Barnes, Wen-Wei Liu, Rebecca Bowermaster, June Clements, Azita Djalilvand, Faith Ough, Joerg Bredno, Andrea Muranyi, Erica N. Heying, Qian Shi, Harry H. Yoon
Purpose:Colorectal cancers with deficient DNA mismatch repair (dMMR) are presumed to uniformly have dense lymphocytic infiltration that underlies their favorable prognosis and is critical to their responsiveness to immunotherapy, as compared with MMR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d3f8547b2d1f14a6c49b48586bc0ae3
https://doi.org/10.1158/1078-0432.c.6528582
https://doi.org/10.1158/1078-0432.c.6528582
Autor:
Frank A. Sinicrope, Kandavel Shanmugam, Steven R. Alberts, Michael Barnes, Wen-Wei Liu, Rebecca Bowermaster, June Clements, Azita Djalilvand, Faith Ough, Joerg Bredno, Andrea Muranyi, Erica N. Heying, Qian Shi, Harry H. Yoon
Table S4. Identification of optimal cutpoint in CD3+ T-cell densities at the invasive margin (CD3+IM) to distinguish overall survival in mismatch repair-deficient stage IIII colon cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bb6698b7f7bd48c8322698b4d6562aa
https://doi.org/10.1158/1078-0432.22473714
https://doi.org/10.1158/1078-0432.22473714
Autor:
Frank A. Sinicrope, Kandavel Shanmugam, Steven R. Alberts, Michael Barnes, Wen-Wei Liu, Rebecca Bowermaster, June Clements, Azita Djalilvand, Faith Ough, Joerg Bredno, Andrea Muranyi, Erica N. Heying, Qian Shi, Harry H. Yoon
Table S5. Identification of optimal cutpoint in CD3+ T-cell densities at the invasive margin (CD3+IM) to distinguish overall survival in mismatch repair-proficient stage IIII colon cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a906d84c84d04da5b0a08eb7c560720
https://doi.org/10.1158/1078-0432.22473711.v1
https://doi.org/10.1158/1078-0432.22473711.v1
Autor:
Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B Yurgelun, Douglas A Rubinson, Deborah Schrag, Shaker R Dakhil, Philip J Stella, Douglas J Weckstein, Donald B Wender, Meredith Faggen, Tyler J Zemla, Erica N Heying, Samantha R Schuetz, Stephanie Noble, Jeffrey A Meyerhardt, Tanios Bekaii-Saab, Charles S Fuchs, Kimmie Ng
Publikováno v:
The Oncologist. 27:292-298
Background Combination irinotecan and cetuximab is approved for irinotecan-refractory metastatic colorectal cancer (mCRC). It is unknown if adding bevacizumab improves outcomes. Patients and Methods In this multicenter, randomized, double-blind, plac
Autor:
Fang-Shu Ou, Tsung Teh Wu, Brenda Ginos, Harry H. Yoon, Timothy F. Drevyanko, Steven R. Alberts, Maged F. Khalil, Gamini S. Soori, Robert J. Behrens, Dennis A. Wigle, Stephen J. Ko, Daniel A. Nikcevich, Robert C. Miller, George P. Kim, Qian Shi, James L. Leenstra, Patrick J. Peller, Robert P. Sticca, Erica N. Heying, Bassam I. Mattar
Publikováno v:
Eur J Cancer
Aim report primary results from the first multicentre randomised trial evaluating induction chemotherapy prior to trimodality therapy in patients with oesophageal or gastro-oesophageal junction adenocarcinoma. Notably, recent data from a single-insti
Autor:
Tanios Bekaii-Saab, Daniel H. Ahn, Erica N. Heying, Patrick McKay Boland, Axel Grothey, Afsaneh Barzi, James M. Cleary, Fang-Shu Ou, Kristen K. Ciombor, Aminah Jatoi, Tyler Zemla, Jeannine S. McCune, Jeff A. Sloan, Boris Pasche, Katrina S. Pedersen, E. Gabriela Chiorean, Nisha L. Jacobs, Heinz-Josef Lenz, Mario E. Lacouture, Jennifer Le-Rademacher
Publikováno v:
Oncologist
Background Hand-foot skin reaction (HFSR) is the most common regorafenib-induced adverse event and is in need of effective prevention and palliation. Materials and Methods The Regorafenib Dose Optimization Study (ReDOS), a four-arm, previously publis